Storia in 5 fonti

Oral Small-Molecule Elecoglipron Tackles Obesity and Diabetes

Investigational pill was well-tolerated and doesn't come with food or water restrictions

Raccontata da

Confronto fonti

5 prospettive sulla stessa storia

AI · summaries

medpagetoday.comStai leggendo1 mese fa

Oral Small-Molecule Elecoglipron Tackles Obesity and Diabetes

Investigational pill was well-tolerated and doesn't come with food or water restrictions

originale

morningstar.com

Timeline cronologica

lunedì 8 giugno 2026·morningstar.com
Novel Once-Daily Pill Delivers Positive Blood Glucose and Weight Reduction Results
Novel Once-Daily Pill Delivers Positive Blood Glucose and Weight Reduction Results
martedì 9 giugno 2026·medpagetoday.com
Oral Small-Molecule Elecoglipron Tackles Obesity and Diabetes
Investigational pill was well-tolerated and doesn't come with food or water restrictions

1 mese fa

Novel Once-Daily Pill Delivers Positive Blood Glucose and Weight Reduction Results

Leggi questa versione → originale

independent.co.uk1 mese fa

AstraZeneca daily pill shows promising weight loss results in trial

Stay up to date with notifications from The IndependentNotifications can be managed in browser preferences.Jump to contentThank you for registeringPlease refresh the page or navigate to another page on the site to be…

Leggi questa versione → originale

benzinga.com1 mese fa

AstraZeneca's GLP-1 Pill Heads To Late-Stage Trials - AstraZeneca (NYSE:AZN)

AstraZeneca advances oral GLP-1 elecoglipron to Phase 3 following strong weight loss & diabetes data at ADA 2026. Get the trial details.

Leggi questa versione → originale

healio.com1 mese fa

GLP-1/amylin receptor agonist lowers HbA1c, weight in type 2 diabetes

Non è possibile riassumere questo articolo per Warptech Tech News. L'articolo tratta endocrinologia/farmacologia (trial clinico di zenagamtide per type 2 diabetes) — non rientra nella topica della testata (AI, Tech, Startup, Business, Infrastructure, Cloud, etc.). Non c'è alcuna implicazione di mercato tech o di stack decisionale per manager IT/CTO. Hai l'articolo corretto da riassumere? 👀

Leggi questa versione → originale

martedì 9 giugno 2026·

benzinga.com

AstraZeneca's GLP-1 Pill Heads To Late-Stage Trials - AstraZeneca (NYSE:AZN)

AstraZeneca advances oral GLP-1 elecoglipron to Phase 3 following strong weight loss & diabetes data at ADA 2026. Get the trial details.

mercoledì 10 giugno 2026·

independent.co.uk

New daily weight loss pill helps people shed 10 per cent of body weight

The pill doesn’t have the fasting requirements of many other weight loss drugs

mercoledì 10 giugno 2026·

independent.co.uk

AstraZeneca daily pill shows promising weight loss results in trial

Stay up to date with notifications from The IndependentNotifications can be managed in browser preferences.Jump to contentThank you for registeringPlease refresh the page or…

venerdì 12 giugno 2026·

healio.com

GLP-1/amylin receptor agonist lowers HbA1c, weight in type 2 diabetes

NEW ORLEANS — A novel unimolecular GLP-1/amylin receptor agonist conferred reductions in HbA1c and body weight for adults with type 2 diabetes, according to data from a phase 2…